Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2024 to Q4 2025

Type / Class
Equity / Common Stock, no par value
Symbol
TELO on Nasdaq
Shares outstanding
34,382,284
Price per share
$1.32
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
2,271,449
Total reported value
$3,021,166
% of total 13F portfolios
0%
Share change
-60,615
Value change
-$87,478
Number of holders
32
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
DEJORIA JOHN PAUL 9.4% +79% $4,315,850 +$1,955,233 3,245,000 +83% John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity 31 Dec 2025

As of 31 Dec 2025, 32 institutional investors reported holding 2,271,449 shares of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO). This represents 6.6% of the company’s total 34,382,284 outstanding shares.

Institutional Holders of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 2,271,449 $3,021,166 -$87,478 $1.33 32
2025 Q3 2,332,205 $3,240,559 -$616,944 $1.39 31
2025 Q2 2,807,449 $3,509,640 -$1,509,843 $1.25 42
2025 Q1 3,692,775 $11,927,929 +$377,557 $3.23 42
2024 Q4 3,563,053 $14,680,234 +$6,102,927 $4.12 37
2024 Q3 2,045,931 $13,136,057 +$9,006,860 $6.42 33
2024 Q2 361,326 $1,737,881 +$1,328,649 $4.81 24
2024 Q1 79,917 $413,466 +$413,466 $5.15 7